A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice
The role of internal dosimetry is usually proposed for investigational purposes in patients treated by RLT, even if its application is not yet the standard method in clinical practice. This limited use is partially justified by several concomitant factors that make calculations a complex process. Th...
Gespeichert in:
| Veröffentlicht in: | European journal of nuclear medicine and molecular imaging 2023-05, Vol.50 (6), p.1753-1764 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1764 |
|---|---|
| container_issue | 6 |
| container_start_page | 1753 |
| container_title | European journal of nuclear medicine and molecular imaging |
| container_volume | 50 |
| creator | Pirozzi Palmese, Valentina D’Ambrosio, Laura Di Gennaro, Francesca Maisto, Costantina de Marino, Roberta Morisco, Anna Coluccia, Sergio Di Gennaro, Piergiacomo De Lauro, Francesco Raddi, Marco Gaballo, Paolo Tafuto, Salvatore Celentano, Egidio Lastoria, Secondo |
| description | The role of internal dosimetry is usually proposed for investigational purposes in patients treated by RLT, even if its application is not yet the standard method in clinical practice. This limited use is partially justified by several concomitant factors that make calculations a complex process. Therefore, simplified dosimetry protocols are required.
Methods
In our study, dosimetric evaluations were performed in thirty patients with NENs who underwent RLT with [
177
Lu]Lu-DOTATATE. The reference method (M0) calculated the cumulative absorbed dose performing dosimetry after each of the four cycles. Obtained data were employed to assess the feasibility of simplified protocols: defining the dosimetry only after the first cycle (M1) and after the first and last one (M2).
Results
The mean differences of the cumulative absorbed doses between M1 and M0 were – 10% for kidney, – 5% for spleen, + 34% for liver, + 13% for red marrow, and + 37% for tumor lesions. Conversely, differences lower than ± 10% were measured between M2 and M0.
Conclusion
Cumulative absorbed doses obtained with the M2 protocol resembled the doses calculated by M0, while the M1 protocol overestimated the absorbed doses in all organs at risk, except for the spleen. |
| doi_str_mv | 10.1007/s00259-023-06112-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10119237</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2803687095</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-c83ef06391ba4823c36eb4524438c2b9a540cf99e984ef4f25348062eb2e52173</originalsourceid><addsrcrecordid>eNp9kstu1DAUhiMEoqXwAiyQJTZlEfAlie0VGpXhIkWthIYVQpbjnMy4SuLUdoqGt-INcZgyXBbIC1s-3_nPOfafZU8Jfkkw5q8CxrSUOaYsxxUhNBf3slNSEZlzLOT945njk-xRCNcYE0GFfJidsKoSQgp8mn1fIeOGSXsb3Ihch4Idpt52Flo0eRedcX1Y7ifwidC9_ZYirUsYRL9HdkSX60s06WhhjAFFDzomotkjr1vrervVY4viDrye9uj8Y715gb7auEOfCef1_KWe8zdXm1VaaxQd6vSt88gmpTnAom56O1qj-9SNNtEaeJw96HQf4MndfpZ9erveXLzP66t3Hy5WdW4KXsbcCAYdrpgkjS4EZYZV0BQlLQomDG2kLgtsOilBigK6oqMlKwSuKDQUSko4O8teH3SnuRmgNWk8r3s1eTtov1dOW_V3ZLQ7tXW3imBCJGWLwvmdgnc3M4SoBhsM9L0ewc1BUZ5-gRBOF_T5P-i1m3167kQJzCrBsSwTRQ-U8S4ED92xG4LVYgl1sIRKllA_LaFESnr25xzHlF8eSAA7ACGFxi3437X_I_sD_eXDXA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2803687095</pqid></control><display><type>article</type><title>A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Pirozzi Palmese, Valentina ; D’Ambrosio, Laura ; Di Gennaro, Francesca ; Maisto, Costantina ; de Marino, Roberta ; Morisco, Anna ; Coluccia, Sergio ; Di Gennaro, Piergiacomo ; De Lauro, Francesco ; Raddi, Marco ; Gaballo, Paolo ; Tafuto, Salvatore ; Celentano, Egidio ; Lastoria, Secondo</creator><creatorcontrib>Pirozzi Palmese, Valentina ; D’Ambrosio, Laura ; Di Gennaro, Francesca ; Maisto, Costantina ; de Marino, Roberta ; Morisco, Anna ; Coluccia, Sergio ; Di Gennaro, Piergiacomo ; De Lauro, Francesco ; Raddi, Marco ; Gaballo, Paolo ; Tafuto, Salvatore ; Celentano, Egidio ; Lastoria, Secondo</creatorcontrib><description>The role of internal dosimetry is usually proposed for investigational purposes in patients treated by RLT, even if its application is not yet the standard method in clinical practice. This limited use is partially justified by several concomitant factors that make calculations a complex process. Therefore, simplified dosimetry protocols are required.
Methods
In our study, dosimetric evaluations were performed in thirty patients with NENs who underwent RLT with [
177
Lu]Lu-DOTATATE. The reference method (M0) calculated the cumulative absorbed dose performing dosimetry after each of the four cycles. Obtained data were employed to assess the feasibility of simplified protocols: defining the dosimetry only after the first cycle (M1) and after the first and last one (M2).
Results
The mean differences of the cumulative absorbed doses between M1 and M0 were – 10% for kidney, – 5% for spleen, + 34% for liver, + 13% for red marrow, and + 37% for tumor lesions. Conversely, differences lower than ± 10% were measured between M2 and M0.
Conclusion
Cumulative absorbed doses obtained with the M2 protocol resembled the doses calculated by M0, while the M1 protocol overestimated the absorbed doses in all organs at risk, except for the spleen.</description><identifier>ISSN: 1619-7070</identifier><identifier>EISSN: 1619-7089</identifier><identifier>DOI: 10.1007/s00259-023-06112-8</identifier><identifier>PMID: 36688980</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Cardiology ; Clinical medicine ; Dosimeters ; Dosimetry ; Humans ; Imaging ; Lutetium isotopes ; Mathematical analysis ; Medicine ; Medicine & Public Health ; Nuclear Medicine ; Octreotide - therapeutic use ; Oncology ; Original ; Original Article ; Orthopedics ; Positron-Emission Tomography ; Radiology ; Radiometry - methods ; Radionuclide Imaging ; Spleen</subject><ispartof>European journal of nuclear medicine and molecular imaging, 2023-05, Vol.50 (6), p.1753-1764</ispartof><rights>The Author(s) 2023. corrected publication 2023</rights><rights>2023. The Author(s).</rights><rights>The Author(s) 2023. corrected publication 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2023, corrected publication 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-c83ef06391ba4823c36eb4524438c2b9a540cf99e984ef4f25348062eb2e52173</citedby><cites>FETCH-LOGICAL-c475t-c83ef06391ba4823c36eb4524438c2b9a540cf99e984ef4f25348062eb2e52173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00259-023-06112-8$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00259-023-06112-8$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36688980$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pirozzi Palmese, Valentina</creatorcontrib><creatorcontrib>D’Ambrosio, Laura</creatorcontrib><creatorcontrib>Di Gennaro, Francesca</creatorcontrib><creatorcontrib>Maisto, Costantina</creatorcontrib><creatorcontrib>de Marino, Roberta</creatorcontrib><creatorcontrib>Morisco, Anna</creatorcontrib><creatorcontrib>Coluccia, Sergio</creatorcontrib><creatorcontrib>Di Gennaro, Piergiacomo</creatorcontrib><creatorcontrib>De Lauro, Francesco</creatorcontrib><creatorcontrib>Raddi, Marco</creatorcontrib><creatorcontrib>Gaballo, Paolo</creatorcontrib><creatorcontrib>Tafuto, Salvatore</creatorcontrib><creatorcontrib>Celentano, Egidio</creatorcontrib><creatorcontrib>Lastoria, Secondo</creatorcontrib><title>A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice</title><title>European journal of nuclear medicine and molecular imaging</title><addtitle>Eur J Nucl Med Mol Imaging</addtitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><description>The role of internal dosimetry is usually proposed for investigational purposes in patients treated by RLT, even if its application is not yet the standard method in clinical practice. This limited use is partially justified by several concomitant factors that make calculations a complex process. Therefore, simplified dosimetry protocols are required.
Methods
In our study, dosimetric evaluations were performed in thirty patients with NENs who underwent RLT with [
177
Lu]Lu-DOTATATE. The reference method (M0) calculated the cumulative absorbed dose performing dosimetry after each of the four cycles. Obtained data were employed to assess the feasibility of simplified protocols: defining the dosimetry only after the first cycle (M1) and after the first and last one (M2).
Results
The mean differences of the cumulative absorbed doses between M1 and M0 were – 10% for kidney, – 5% for spleen, + 34% for liver, + 13% for red marrow, and + 37% for tumor lesions. Conversely, differences lower than ± 10% were measured between M2 and M0.
Conclusion
Cumulative absorbed doses obtained with the M2 protocol resembled the doses calculated by M0, while the M1 protocol overestimated the absorbed doses in all organs at risk, except for the spleen.</description><subject>Cardiology</subject><subject>Clinical medicine</subject><subject>Dosimeters</subject><subject>Dosimetry</subject><subject>Humans</subject><subject>Imaging</subject><subject>Lutetium isotopes</subject><subject>Mathematical analysis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nuclear Medicine</subject><subject>Octreotide - therapeutic use</subject><subject>Oncology</subject><subject>Original</subject><subject>Original Article</subject><subject>Orthopedics</subject><subject>Positron-Emission Tomography</subject><subject>Radiology</subject><subject>Radiometry - methods</subject><subject>Radionuclide Imaging</subject><subject>Spleen</subject><issn>1619-7070</issn><issn>1619-7089</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kstu1DAUhiMEoqXwAiyQJTZlEfAlie0VGpXhIkWthIYVQpbjnMy4SuLUdoqGt-INcZgyXBbIC1s-3_nPOfafZU8Jfkkw5q8CxrSUOaYsxxUhNBf3slNSEZlzLOT945njk-xRCNcYE0GFfJidsKoSQgp8mn1fIeOGSXsb3Ihch4Idpt52Flo0eRedcX1Y7ifwidC9_ZYirUsYRL9HdkSX60s06WhhjAFFDzomotkjr1vrervVY4viDrye9uj8Y715gb7auEOfCef1_KWe8zdXm1VaaxQd6vSt88gmpTnAom56O1qj-9SNNtEaeJw96HQf4MndfpZ9erveXLzP66t3Hy5WdW4KXsbcCAYdrpgkjS4EZYZV0BQlLQomDG2kLgtsOilBigK6oqMlKwSuKDQUSko4O8teH3SnuRmgNWk8r3s1eTtov1dOW_V3ZLQ7tXW3imBCJGWLwvmdgnc3M4SoBhsM9L0ewc1BUZ5-gRBOF_T5P-i1m3167kQJzCrBsSwTRQ-U8S4ED92xG4LVYgl1sIRKllA_LaFESnr25xzHlF8eSAA7ACGFxi3437X_I_sD_eXDXA</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Pirozzi Palmese, Valentina</creator><creator>D’Ambrosio, Laura</creator><creator>Di Gennaro, Francesca</creator><creator>Maisto, Costantina</creator><creator>de Marino, Roberta</creator><creator>Morisco, Anna</creator><creator>Coluccia, Sergio</creator><creator>Di Gennaro, Piergiacomo</creator><creator>De Lauro, Francesco</creator><creator>Raddi, Marco</creator><creator>Gaballo, Paolo</creator><creator>Tafuto, Salvatore</creator><creator>Celentano, Egidio</creator><creator>Lastoria, Secondo</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20230501</creationdate><title>A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice</title><author>Pirozzi Palmese, Valentina ; D’Ambrosio, Laura ; Di Gennaro, Francesca ; Maisto, Costantina ; de Marino, Roberta ; Morisco, Anna ; Coluccia, Sergio ; Di Gennaro, Piergiacomo ; De Lauro, Francesco ; Raddi, Marco ; Gaballo, Paolo ; Tafuto, Salvatore ; Celentano, Egidio ; Lastoria, Secondo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-c83ef06391ba4823c36eb4524438c2b9a540cf99e984ef4f25348062eb2e52173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cardiology</topic><topic>Clinical medicine</topic><topic>Dosimeters</topic><topic>Dosimetry</topic><topic>Humans</topic><topic>Imaging</topic><topic>Lutetium isotopes</topic><topic>Mathematical analysis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nuclear Medicine</topic><topic>Octreotide - therapeutic use</topic><topic>Oncology</topic><topic>Original</topic><topic>Original Article</topic><topic>Orthopedics</topic><topic>Positron-Emission Tomography</topic><topic>Radiology</topic><topic>Radiometry - methods</topic><topic>Radionuclide Imaging</topic><topic>Spleen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pirozzi Palmese, Valentina</creatorcontrib><creatorcontrib>D’Ambrosio, Laura</creatorcontrib><creatorcontrib>Di Gennaro, Francesca</creatorcontrib><creatorcontrib>Maisto, Costantina</creatorcontrib><creatorcontrib>de Marino, Roberta</creatorcontrib><creatorcontrib>Morisco, Anna</creatorcontrib><creatorcontrib>Coluccia, Sergio</creatorcontrib><creatorcontrib>Di Gennaro, Piergiacomo</creatorcontrib><creatorcontrib>De Lauro, Francesco</creatorcontrib><creatorcontrib>Raddi, Marco</creatorcontrib><creatorcontrib>Gaballo, Paolo</creatorcontrib><creatorcontrib>Tafuto, Salvatore</creatorcontrib><creatorcontrib>Celentano, Egidio</creatorcontrib><creatorcontrib>Lastoria, Secondo</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>European journal of nuclear medicine and molecular imaging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pirozzi Palmese, Valentina</au><au>D’Ambrosio, Laura</au><au>Di Gennaro, Francesca</au><au>Maisto, Costantina</au><au>de Marino, Roberta</au><au>Morisco, Anna</au><au>Coluccia, Sergio</au><au>Di Gennaro, Piergiacomo</au><au>De Lauro, Francesco</au><au>Raddi, Marco</au><au>Gaballo, Paolo</au><au>Tafuto, Salvatore</au><au>Celentano, Egidio</au><au>Lastoria, Secondo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice</atitle><jtitle>European journal of nuclear medicine and molecular imaging</jtitle><stitle>Eur J Nucl Med Mol Imaging</stitle><addtitle>Eur J Nucl Med Mol Imaging</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>50</volume><issue>6</issue><spage>1753</spage><epage>1764</epage><pages>1753-1764</pages><issn>1619-7070</issn><eissn>1619-7089</eissn><abstract>The role of internal dosimetry is usually proposed for investigational purposes in patients treated by RLT, even if its application is not yet the standard method in clinical practice. This limited use is partially justified by several concomitant factors that make calculations a complex process. Therefore, simplified dosimetry protocols are required.
Methods
In our study, dosimetric evaluations were performed in thirty patients with NENs who underwent RLT with [
177
Lu]Lu-DOTATATE. The reference method (M0) calculated the cumulative absorbed dose performing dosimetry after each of the four cycles. Obtained data were employed to assess the feasibility of simplified protocols: defining the dosimetry only after the first cycle (M1) and after the first and last one (M2).
Results
The mean differences of the cumulative absorbed doses between M1 and M0 were – 10% for kidney, – 5% for spleen, + 34% for liver, + 13% for red marrow, and + 37% for tumor lesions. Conversely, differences lower than ± 10% were measured between M2 and M0.
Conclusion
Cumulative absorbed doses obtained with the M2 protocol resembled the doses calculated by M0, while the M1 protocol overestimated the absorbed doses in all organs at risk, except for the spleen.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36688980</pmid><doi>10.1007/s00259-023-06112-8</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1619-7070 |
| ispartof | European journal of nuclear medicine and molecular imaging, 2023-05, Vol.50 (6), p.1753-1764 |
| issn | 1619-7070 1619-7089 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10119237 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Cardiology Clinical medicine Dosimeters Dosimetry Humans Imaging Lutetium isotopes Mathematical analysis Medicine Medicine & Public Health Nuclear Medicine Octreotide - therapeutic use Oncology Original Original Article Orthopedics Positron-Emission Tomography Radiology Radiometry - methods Radionuclide Imaging Spleen |
| title | A comparison of simplified protocols of personalized dosimetry in NEN patients treated by radioligand therapy (RLT) with [177Lu]Lu-DOTATATE to favor its use in clinical practice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A12%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20comparison%20of%20simplified%20protocols%20of%20personalized%20dosimetry%20in%20NEN%20patients%20treated%20by%20radioligand%20therapy%20(RLT)%20with%20%5B177Lu%5DLu-DOTATATE%20to%20favor%20its%20use%20in%20clinical%20practice&rft.jtitle=European%20journal%20of%20nuclear%20medicine%20and%20molecular%20imaging&rft.au=Pirozzi%20Palmese,%20Valentina&rft.date=2023-05-01&rft.volume=50&rft.issue=6&rft.spage=1753&rft.epage=1764&rft.pages=1753-1764&rft.issn=1619-7070&rft.eissn=1619-7089&rft_id=info:doi/10.1007/s00259-023-06112-8&rft_dat=%3Cproquest_pubme%3E2803687095%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2803687095&rft_id=info:pmid/36688980&rfr_iscdi=true |